Peripheral Neuropathy clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
open to eligible people ages 18 years and up
This is a randomized, double-blind, placebo-controlled adaptive study of the safety, tolerability, and exploratory efficacy of once-daily topical WST-057 administered for up to 19 weeks (or up to 24 weeks for subjects who experience a chemotherapy dose delay) to subjects who are also receiving 6 cycles (3 weeks apart) of Carboplatin AUC 5-6 and Paclitaxel 175 mg/m2 (with dose adjustment per institutional guidelines permitted).
Orange, California and other locations
Our lead scientists for Peripheral Neuropathy research studies include Jill Tseng, MD.
Last updated: